| Recruitment status | Preinitiation |
| Unique ID issued by UMIN | UMIN000022873 |
| Receipt No. | R000026357 |
| Official scientific title of the study | Study of glucocorticoid-induced osteoporosis prevention in patients with glomerulonephritis |
| Date of disclosure of the study information | 2016/07/01 |
| Last modified on | 2016/06/24 (Ver. 1) |
| Basic information | ||
| Official scientific title of the study | Study of glucocorticoid-induced osteoporosis prevention in patients with glomerulonephritis | |
| Title of the study (Brief title) | Study of glucocorticoid-induced osteoporosis prevention in patients with glomerulonephritis | |
| Region |
|
|
| Condition | ||
| Condition | glomerulonephritis | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | To evaluate the efficacy and safety of denosumab and alendronate sodium in patients with glomerulonephritis.
|
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | Confirmatory |
| Trial characteristics_2 | |
| Developmental phase | Phase III |
| Assessment | |
| Primary outcomes | change of bone mineral density |
| Key secondary outcomes | change of bone turnover markers, proteinuria, kidney function |
| In outcomes field, the entry of just a few words such as "safety" or "efficiency" will not be accepted. Specify the name of outcome measures, including the time when you plan to measure. Usually, only one primary outcome is accepted. Write the other outcomes in "secondary outcomes" field. |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Open -no one is blinded |
| Control | Active |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Prevention | |
| Type of intervention |
|
|
| Interventions/Control_1 | denosumab 60mg subcutaneously once in 6 months | |
| Interventions/Control_2 | alendronate sodium 35mg orally every week | |
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| In interventions field, include the details of interventions, such as duration, amount, and frequency. If the intervention includes prescription or use of medical devices, duration is required. |
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | Patients with glomerulonephritis planned to be treated with steroid for over 6 months in our hospital. | |||
| Key exclusion criteria | 1.Cases where no consent is obtained.
2.Patients allergic to alendronate sodium or denosumab. 3.Patients pregnant or potential. 4.Other cases where physicians regard as inappropriate. |
|||
| Target sample size | 40 | |||
| Research contact person | |
| Name of lead principal investigator | Kentaro Nakai |
| Organization | Kakogawa central city hospital |
| Division name | department of Nephrology and kidney center |
| Address | 384-1 Hiradu,Yonedacho,Kakogawa city |
| TEL | 0794323531 |
| kentaro-kyu@umin.net | |
| Public contact | |
| Name of contact person | Kei saitoh |
| Organization | Kakogawa central city hospital |
| Division name | department of Nephrology and kidney center |
| Address | 384-1 Hiradu,Yonedacho,Kakogawa city |
| TEL | 0794323531 |
| Homepage URL | |
| kei.saitoh0705@gmail.com | |
| Sponsor | |
| Institute | Kakogawa central city hospital |
| Institute | |
| Department | |
| Sponsor means an organization that is responsible for plan, deployment and report of the research including funding management. It doesn't mean funding agency". Therefore, all clinical trial should have the one. |
| Funding Source | |
| Organization | Kakogawa central city hospital |
| Organization | |
| Division | |
| Category of Funding Organization | Other |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Preinitiation | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000026357 |